Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Monjuvi (tafasitamab-cxix)
i
Other names:
MOR208, MOR-00208, XmAb5574, XENP-5574, MOR-208, MOR 208, MOR00208, INCMOR0208, ICP-B04, ICPB04, ICP B04, INCMOR-0208, INCMOR 0208, MOR 00208, XENP5574, XENP 5574, XmAb 5574, XmAb-5574
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(3)
News
Trials
Company:
Incyte, InnoCare, Knight Therap, Specialised Therap, Xencor
Drug class:
CD19 inhibitor
Related drugs:
‹
blinatumomab (52)
A-319 (2)
FT596 (2)
CLN-978 (1)
YT-19 (1)
AFM11 (0)
ALA-101 (0)
AMG 562 (0)
AZD0486 (0)
BTN2A1/3A1-Fc-CD19scFv (0)
CAR-NK-CD19 cells (0)
CAR19-CYNK (0)
CB CAR-NK019 (0)
CD19.t-haNK (0)
CMG1A46 (0)
CNTY-101 (0)
Imtox19/Imtox22 (0)
ET-190 (0)
FT522 (0)
GNR-084 (0)
JD001 (0)
JD010 (0)
KN5501 (0)
NKX019 (0)
ONKT101 (0)
PIT565 (0)
QN-019a (0)
RG6333 (0)
RGV004 (0)
SNC103 (0)
TAC01-CD19 (0)
TAK-007 (0)
TC-110 (0)
TG-1801 (0)
inebilizumab-cdon (0)
YT-19/22 (0)
anti CD19/CD22 CAR NK cells (0)
autologous TRAC locus-inserted CD19-STAR-T (0)
dualCAR-NK19/70 (0)
GNC-038 (0)
RG6076 (0)
CF33-CD19 (0)
universal chimeric antigen receptor-modified AT19 cells (0)
blinatumomab (52)
A-319 (2)
FT596 (2)
CLN-978 (1)
YT-19 (1)
AFM11 (0)
ALA-101 (0)
AMG 562 (0)
AZD0486 (0)
BTN2A1/3A1-Fc-CD19scFv (0)
CAR-NK-CD19 cells (0)
CAR19-CYNK (0)
CB CAR-NK019 (0)
CD19.t-haNK (0)
CMG1A46 (0)
CNTY-101 (0)
Imtox19/Imtox22 (0)
ET-190 (0)
FT522 (0)
GNR-084 (0)
JD001 (0)
JD010 (0)
KN5501 (0)
NKX019 (0)
ONKT101 (0)
PIT565 (0)
QN-019a (0)
RG6333 (0)
RGV004 (0)
SNC103 (0)
TAC01-CD19 (0)
TAK-007 (0)
TC-110 (0)
TG-1801 (0)
inebilizumab-cdon (0)
YT-19/22 (0)
anti CD19/CD22 CAR NK cells (0)
autologous TRAC locus-inserted CD19-STAR-T (0)
dualCAR-NK19/70 (0)
GNC-038 (0)
RG6076 (0)
CF33-CD19 (0)
universal chimeric antigen receptor-modified AT19 cells (0)
›
Associations
(3)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
lenalidomide + tafasitamab-cxix
Sensitive: A1 - Approval
lenalidomide + tafasitamab-cxix
Sensitive
:
A1
lenalidomide + tafasitamab-cxix
Sensitive: A1 - Approval
lenalidomide + tafasitamab-cxix
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
lenalidomide + tafasitamab-cxix
Sensitive: C3 – Early Trials
lenalidomide + tafasitamab-cxix
Sensitive
:
C3
lenalidomide + tafasitamab-cxix
Sensitive: C3 – Early Trials
lenalidomide + tafasitamab-cxix
Sensitive
:
C3
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
lenalidomide + tafasitamab-cxix
Sensitive: C3 – Early Trials
lenalidomide + tafasitamab-cxix
Sensitive
:
C3
lenalidomide + tafasitamab-cxix
Sensitive: C3 – Early Trials
lenalidomide + tafasitamab-cxix
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login